Juntendo Medical Journal
Online ISSN : 2188-2134
Print ISSN : 0022-6769
ISSN-L : 0022-6769
Volume 40, Issue 4
Displaying 1-19 of 19 articles from this issue
Contents
  • 大蔵 隆一
    1995 Volume 40 Issue 4 Pages 423-428
    Published: March 16, 1995
    Released on J-STAGE: November 18, 2014
    JOURNAL FREE ACCESS
    Recently, endoscopic resection (ER) has been performed for early gastric cancer or adenoma. After this procedure, a round gastric ulcer 10 to 30 mm in diameter remained. The ulcer was penetrated to the submucosa. This study examined the relationship between Helicobacter pylori (H. pylori) infection and the healing of such an artificial gastric ulcer induced by ER in humans. ER was performed in 45 patients with early gastric cancer or adenoma to resect those lesions. The healing process of the ulcer was followed by endoscopy at 3 days, 2 weeks, 2 months and 6 months after ER. At each examination, the presence of H. pylori in the gastric mucosa was examined. Biopsy specimens were taken from 3 sites (lesser curvature of the antrum, greater curvature of the gastric body and ulcer edge), and cultured in Dent's medium for detection of H. pylori. Three days after ER, all ulcers remained in the active stage, but 2 months after ER, all ulcers had healed up to scar formation peyard less of whether H. pylori was positive or negative in the gastric mucosa adjacent to the ulcer. No relapse of ulcer was recognized up to 490 days in the longest follow up (average 296. 1 days) after the ulcer had healed. The detection rate of H. pylori at the time of ER was 34.1% and 6 months after ER, it was 65.4%. In conclusion, the healing process of gastric ulcer induced by ER was not retarded by H. pylori infection, and relapse of the ulcer was not recognized. It is concluded that there is no causal relationship between H. pylori infection and the healing process or relapse of gastric ulcers induced by ER.
    Download PDF (835K)
  • 船曳 均
    1995 Volume 40 Issue 4 Pages 429-440
    Published: March 16, 1995
    Released on J-STAGE: November 18, 2014
    JOURNAL FREE ACCESS
    Chemosensitivity tests of anticancer agents for 60 resected human gastric cancers were performed using the adhesive tumor cell culture system (ATCCS) to clarify the sensitivity of gastric cancer cells to anticancer agents. The usefulness of this test for gastric cancer cases was studied. The relationship between the macroscopic types or the histological types of cancer and the chemosensitivity was also studied. More than 2.5×105, viable cancer cells which were the number of cells required to evaluate the test for 7 drugs, was obtained in 71.7% of all cases. The specimen weight was important for the test to successful. Chemosensitivity could be evaluated in 32 (74.4%) of the 43 cases in which the required number of viable cancer cells were obtained for the test. The major reason for evaluation failure was fungal contamination. Seventeen of the 32 evaluable cases (53.1%) were sensitive to the anticancer agents. Especially 8 cases (25.0%) were sensitive to more than 2 drugs. The macroscopic type of cancer made no difference in the chemosensitivity. The sensitivity of the gastric cancer cells for several drugs was higher in the cases with the histologically, undifferentiated type than in the cases with the differentiated type, and all of the cases sensitive to more than 3 drugs were undifferentiated type. Also, the rate of the sensitivity for each drug showed no difference with the macroscopic types, but the sensitivity was higher in the cases with the undifferentiated type for 5 of the 7 tested drugs. The sensitivity for 5 -fluorouracil (5-FU) or cisplatin (CDDP) was especially higher in the cases with the undifferentiated type. Gastric cancer cells which were sensitive to several drugs showed a tendency to be sensitive especially to 5 -FU or CDDP.
    Download PDF (1726K)
  • SUNG Wook YANG
    1995 Volume 40 Issue 4 Pages 441-451
    Published: March 16, 1995
    Released on J-STAGE: November 18, 2014
    JOURNAL FREE ACCESS
    Survival was evalvated based on factors affecting the prognosis after EIS was performad for esophageal varices. EIS was performed in 69 cases between January, 1989 and September, 1993. There were 48 male and 21 female patients with a mean age of 57 years. There were 64 cases of liver cirrhosis, including 20 cases of hepatocellular carcinoma (HCC), 3 primary biliary cirrhosis cases and 2 other cases. Child classification, timing of treatment, presence of HCC, bleeding after EIS, and recurrent varices were evaluated as factors affecting the prognosis of EIS using cumulative survival probability. The primary factor affecting the prognosis was Child the classifieation C. Second was HCC, third emergency status and fourth bleeding after EIS. The prognosis was worst in cases that overlapped Child C with HCC or emergency. In elective cases, bleeding could be stopped conservatively. There was no difference between the prophylactic cases and elective cases in prognosis. Therefore we concluded that EIS should be performed in bleeding cases after improving the patient's general condition because those with bleeding after EIS had a worse prognosis than those with recurrent varices, Additional EIS should be performed to prevent bleeding. Survival was less than 2 years in emergent cases, HCC cases with VP 3 or H3, or in Child C cases showing bleeding after EIS. The survival duration was within 3 years in cases showing 2 mg/dl or more of T-bilirubin, less 3 g/dl of albumin, or uncontrollable ascites. It was concluded that prophylactic and/or additional EIS might be indicated in patients with high varices before the appearance of HCC with VP 3 or H 3 or progression to Child C classification.
    Download PDF (1374K)
  • SEIRO SHIOMI
    1995 Volume 40 Issue 4 Pages 452-463
    Published: March 16, 1995
    Released on J-STAGE: November 18, 2014
    JOURNAL FREE ACCESS
    Liver metastasis is an important factor influencing the prognosis of colon cancer, and the coagulation system is related to hematogenous metastasis of cancer. This study investigated whether inhibition of platelet aggregation is of benefit in preventing liver metastasis of colon cancer, using a hematogenous metastatic model of mouse colon cancer, Colon26. A stable derivative of Prostaglandin I2, beraprost sodium (TRK100), was used as an antiplatelet aggregation drug. It was confirmed that Colon26 had platelet aggregating activity and that TRK100 dosedependently inhibited this activity. The influence of differences in the durations, dose and routes of administration of TRK100 on the liver metastasis duration, dose and routes of administration of TRK100 on the liver metastasis of Colon26 was investigated. When TRK100 was administered intraportally prior to injection of Colon26, the number of metastatic nodules was decreased significantly. The three doses of TRK100 used included 0.01mg/kg, 0.1mg/kg and 1 mg/kg via the portal and oral routes. With portal administration of TRK100, the number of metastatic nodules was reduced significantly and the survival period was prolonged in all dose groups. Furthermore, with oral administration, the number of metastatic nodules decreased significantly and the survival period was prolonged in groups receiving doses of 0.1mg/kg and 1 mg/kg of TRK100. The inhibitor of PGI2 synthesis, 15HPETE increased the number of metastatic nodules and the liver weight significantly. These findings suggest that TRK100 suppresses liver metastasis through the mechanism of inhibiting the platelet aggregating activity of Colon26 and that TRK100 may be a useful preventive therapy against metastasis during the perioperative period.
    Download PDF (2157K)
  • 山村 彰彦, 丹野 正隆, 和田 了, 鈴木 不二彦, 桑原 紀之, 芳川 洋, 村石 世志野, 梁井 皎
    1995 Volume 40 Issue 4 Pages 464-469
    Published: March 16, 1995
    Released on J-STAGE: November 18, 2014
    JOURNAL FREE ACCESS
    Download PDF (3163K)
  • --We can diagnose that for using of the immunological genetic study--
    RIE YOSHIKATA, MASANOBU NISHIDA, TOSHIHARU MATSUMOTO
    1995 Volume 40 Issue 4 Pages 470-474
    Published: March 16, 1995
    Released on J-STAGE: November 18, 2014
    JOURNAL FREE ACCESS
    Many cases of the malignant lymphoma of the orbit involve a low grade malignancy and it is very hard to differentiate between malignant lymphoma or pseudo lymphoma. Sometimes we can not make a differential diagnosis of these two diseases by microscopic study only. Recently immunological genetic study has been used to diagnose malignat lymphoma. We encountered a 79-year-old man with malignant lymphoma. Seven years ago, he had an orbital tumor on the right side. That tumor was diagnosed as pseudo lymphoma. Then again he an orbital tumor developed on the left side. We extirpated the tumor and were able to dignose malignant lymphoma by immunological genetic study. In this paper, we present a case of malignant lymphoma and discuss the diagnosis and treatment.
    Download PDF (1385K)
feedback
Top